Rangwala Reshma's Insider Trades & SAST Disclosures
Rangwala Reshma's most recent trade in Karyopharm Therapeutics Inc was a trade of 3,587 Common Stock done at an average price of $6.3 . Disclosure was reported to the exchange on March 4, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Rangwala Reshma.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
|
Karyopharm Therapeutics Inc
|
Reshma Rangwala | EVP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 6.29 per share. | 04 Mar 2025 | 3,587 | 29,272 (0%) | 0% | 6.3 | 22,562 | Common Stock |
|
Karyopharm Therapeutics Inc
|
Reshma Rangwala | EVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 10,833 | 10,833 | - | - | Stock Option (right to buy) | |
|
Karyopharm Therapeutics Inc
|
Reshma Rangwala | EVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 9,166 | 9,166 | - | - | Stock Option (right to buy) | |
|
Karyopharm Therapeutics Inc
|
Reshma Rangwala | EVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 5,416 | 28,276 (0%) | 0% | 0 | Common Stock | |
|
Karyopharm Therapeutics Inc
|
Reshma Rangwala | EVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 4,583 | 32,859 (0%) | 0% | 0 | Common Stock | |
|
Karyopharm Therapeutics Inc
|
Reshma Rangwala | EVP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 1.17 per share. | 22 Apr 2024 | 6,789 | 342,931 (0%) | 0% | 1.2 | 7,943 | Common Stock |
|
Karyopharm Therapeutics Inc
|
Reshma Rangwala | EVP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 1.17 per share. | 29 Feb 2024 | 15,667 | 355,689 (0%) | 0% | 1.2 | 18,330 | Common |
|
Karyopharm Therapeutics Inc
|
Reshma Rangwala | EVP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 1.20 per share. | 29 Feb 2024 | 5,969 | 349,720 (0%) | 0% | 1.2 | 7,163 | Common |
|
Karyopharm Therapeutics Inc
|
Rangwala Reshma | EVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2024 | 198,959 | 371,356 (0%) | 0% | 0 | Common Stock | |
|
Karyopharm Therapeutics Inc
|
Rangwala Reshma | EVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 14,167 | 172,397 (0%) | 0% | 0 | Common Stock | |
|
Karyopharm Therapeutics Inc
|
Reshma Rangwala | EVP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 4.05 per share. | 20 Apr 2023 | 6,655 | 158,230 (0%) | 0% | 4.1 | 26,953 | Common Stock |
|
Karyopharm Therapeutics Inc
|
Reshma Rangwala | EVP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 4.03 per share. | 20 Apr 2023 | 115 | 164,885 (0%) | 0% | 4.0 | 463 | Common Stock |
|
Karyopharm Therapeutics Inc
|
Reshma Rangwala | EVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 100,000 | 165,000 (0%) | 0% | 0 | Common Stock | |
|
Karyopharm Therapeutics Inc
|
Reshma Rangwala | EVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Apr 2022 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
|
Karyopharm Therapeutics Inc
|
Reshma Rangwala | EVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Apr 2022 | 65,000 | 65,000 (0%) | 0% | 0 | Common Stock | |
|
Aravive Inc
|
Reshma Rangwala | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2022 | 175,000 | 175,000 | - | - | Stock Option (Right to buy) | |
|
Aravive Inc
|
Reshma Rangwala | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2021 | 10,000 | 10,000 | - | - | Stock Options | |
|
Aravive Inc
|
Reshma Rangwala | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Sep 2020 | 75,000 | 75,000 | - | - | Stock Option |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges